Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: Impact on survival and bacterial resistance

Critical Care

Volumn 17, Issue 6, 2013, Pages

  Adrie, Christophe ^a,b   Schwebel, Carole ^c   Garrouste Orgeas, Maïté ^c,d   Vignoud, Lucile ^c   Planquette, Benjamin ^e   Azoulay, Elie ^f   Kallel, Hatem ^g   Darmon, Michael ^h   Souweine, Bertrand ⁱ   Dinh Xuan, Anh Tuan ^a   Jamali, Samir ^j   Zahar, Jean Ralph ^k   Timsit, Jean François ^c  

^a Paris University ^*  (France)

^b DELAFONTAINE HOSPITAL   (France)

^c UNIV GRENOBLE ALPES   (France)

^d SAINT JOSEPH HOSPITAL   (France)

^e CENTRE HOSPITALIER DE VERSAILLES   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g Parasitology Mycology Laboratory   (France)

^h UNIVERSITÉ JEAN MONNET   (France)

ⁱ SERVICE DE RHUMATOLOGIE   (France)

^j Dourdan Hospital   (France)

^k HÔPITAL NECKER ENFANTS MALADES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM; CIPROFLOXACIN; LEVOFLOXACIN; MACROLIDE; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CRITICALLY ILL PATIENT; DISEASE SEVERITY; FEMALE; FRANCE; GENDER; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SEPTIC SHOCK; STREPTOCOCCUS PNEUMONIA; COMMUNITY-ACQUIRED INFECTIONS; CRITICAL ILLNESS; CROSS INFECTION; DRUG COMBINATION; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; SURVIVAL; TIME;

AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; COMMUNITY-ACQUIRED INFECTIONS; CRITICAL ILLNESS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; FRANCE; HUMANS; INTENSIVE CARE UNITS; MACROLIDES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84887362831     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13095     Document Type: Article

References (41)

1. Adrie C, Alberti C, Chaix-Couturier C, Azoulay E, De Lassence A, Cohen Y, Meshaka P, Cheval C, Thuong M, Troché G, Garrouste-Orgeas M, Timsit JF. Epidemiology and economic evaluation of severe sepsis in France: age, severity, infection site, and place of acquisition (community, hospital, or intensive care unit) as determinants of workload and cost. J Crit Care 2005, 20:46-58. 10.1016/j.jcrc.2004.10.005, 16015516.
2. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Dodek P, Wood G, Kumar A, Simon D, Peters C, Ahsan M, Chateau D,. Cooperative Antimicrobial Therapy of Septic Shock Database Research Group Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009, 136:1237-1248. 10.1378/chest.09-0087, 19696123, Cooperative Antimicrobial Therapy of Septic Shock Database Research Group.
3. Rodríguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Solé-Violán J, Rello J,. CAPUCI Study Group Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007, 35:1493-1498. 10.1097/01.CCM.0000266755.75844.05, 17452932, CAPUCI Study Group.
4. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, Macfarlane JT, Read RC, Roberts HJ, Levy ML, Wani M, Woodhead MA,. Pneumonia Guidelines Committee of the BTS Standards of Care Committee BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009, 64:iii1-iii55. Pneumonia Guidelines Committee of the BTS Standards of Care Committee.
5. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG,. Infectious Diseases Society of America; American Thoracic Society Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44:S27-S72. 10.1086/511159, 17278083, Infectious Diseases Society of America; American Thoracic Society.
6. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Read R, Verheij TJ,. Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 2011, 17:E1-E59. Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases.
7. Caballero J, Rello J. Combination antibiotic therapy for community-acquired pneumonia. Ann Intensive Care 2011, 1:48. 10.1186/2110-5820-1-48, 3248869, 22113077.
8. Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garnacho-Montero J, Restrepo MI, Rello J. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010, 36:612-620. 10.1007/s00134-009-1730-y, 19953222.
9. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, Chedid MB, Hui DS, Andremont A, Chiou CC,. International Pneumococcal Study Group Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004, 170:440-444. 10.1164/rccm.200311-1578OC, 15184200, International Pneumococcal Study Group.
10. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The impact of empiric antimicrobial therapy with a beta-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care 2005, 10:R8. 1550860, 16420641.
11. Burgess DS, Lewis JS. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther 2000, 22:872-878. 10.1016/S0149-2918(00)80059-4, 10945513.
12. Dwyer R, Ortqvist A, Aufwerber E, Henriques-Normark B, Marrie TJ, Mufson MA, Torres A, Woodhead MA, Alenius M, Kalin M. Addition of a macrolide to a SS-lactam in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2006, 25:518-521. 10.1007/s10096-006-0183-2, 16896822.
13. Harbarth S, Garbino J, Pugin J, Romand JA, Pittet D. Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur J Clin Microbiol Infect Dis 2005, 24:688-690. 10.1007/s10096-005-0018-6, 16215712.
14. Leroy O, Saux P, Bédos JP, Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005, 128:172-183. 10.1378/chest.128.1.172, 16002932.
15. Rello J, Lisboa T, Lujan M, Gallego M, Kee C, Kay I, Lopez D, Waterer GW,. DNA-Neumococo Study Group Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest 2009, 136:832-840. 10.1378/chest.09-0258, 19433527, DNA-Neumococo Study Group.
16. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010, 23:590-615. 10.1128/CMR.00078-09, 2901655, 20610825.
17. Martinez FJ. Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients. Clin Infect Dis 2004, 38:S328-S340. 10.1086/382689, 15127366.
18. Shefet D, Robenshtok E, Paul M, Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med 2005, 165:1992-2000. 10.1001/archinte.165.17.1992, 16186469.
19. Keeley D. Guidelines for managing community acquired pneumonia in adults. BMJ 2002, 324:436-437. 10.1136/bmj.324.7335.436, 1122378, 11859031.
20. Misset B, Nakache D, Vesin A, Darmon M, Garrouste-Orgeas M, Mourvillier B, Adrie C, Pease S, de Beauregard MA, Goldgran-Toledano D, Métais E, Timsit JF,. Outcomerea Database Investigators Reliability of diagnostic coding in intensive care patients. Crit Care 2008, 12:R95. 10.1186/cc6969, 2575581, 18664267, Outcomerea Database Investigators.
21. Kollef MH, Micek ST. Patients hospitalized with pneumonia: determining the need for broad-spectrum antibiotic therapy. Clin Infect Dis 2012, 54:479-482. 10.1093/cid/cir848, 22109952.
22. Pham LH, Brun-Buisson C, Legrand P, Rauss A, Verra F, Brochard L, Lemaire F. Diagnosis of nosocomial pneumonia in mechanically ventilated patients. Comparison of a plugged telescoping catheter with the protected specimen brush. Am Rev Respir Dis 1991, 143:1055-1061. 10.1164/ajrccm/143.5_Pt_1.1055, 2024814.
23. Calandra T, Cohen J,. International Sepsis Forum Definition of Infection in the ICU Consensus Conference The International Sepsis Forum Consensus Conference on Definitions of Infection in the Intensive Care Unit. Crit Care Med 2005, 33:1538-1548. 10.1097/01.CCM.0000168253.91200.83, 16003060, International Sepsis Forum Definition of Infection in the ICU Consensus Conference.
24. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1995, 20:864-874. .
25. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
26. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58:377-382. 10.1136/thorax.58.5.377, 1746657, 12728155.
27. Cillóniz C, Ewig S, Polverino E, Marcos MA, Esquinas C, Gabarrús A, Mensa J, Torres A. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011, 66:340-346. 10.1136/thx.2010.143982, 21257985.
28. Ewig S, Welte T, Chastre J, Torres A. Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 2010, 10:279-287. 10.1016/S1473-3099(10)70032-3, 20334851.
29. Adrie C, Azoulay E, Francais A, Clec'h C, Darques L, Schwebel C, Nakache D, Jamali S, Goldgran-Toledano D, Garrouste-Orgeas M, Timsit JF,. OutcomeRea Study Group Influence of gender on the outcome of severe sepsis: a reappraisal. Chest 2007, 132:1786-1793. 10.1378/chest.07-0420, 17890473, OutcomeRea Study Group.
30. Zahar JR, Timsit JF, Garrouste-Orgeas M, Francais A, Vesim A, Descorps-Declere A, Dubois Y, Souweine B, Haouache H, Goldgran-Toledano D, Allaouchiche B, Azoulay E, Adrie C. Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality. Crit Care Med 2011, 39:1886-1895. Erratum in: Crit Care Med 2011, 39:2392. Vesim, Aurélien [corrected to Vesin, Aurélien], 10.1097/CCM.0b013e31821b827c, 21516036.
31. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596. 10.1097/01.CCM.0000217961.75225.E9, 16625125.
32. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, Weber GF, Petrillo MK, Houck PM, Fine JM. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997, 278:2080-2084. 10.1001/jama.1997.03550230056037, 9403422.
33. Jacobs MR. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. Clin Infect Dis 2002, 35:565-569. 10.1086/341980, 12173130.
34. Weiss K, Tillotson GS. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. Chest 2005, 128:940-946. 10.1378/chest.128.2.940, 16100190.
35. Alvarez J, Dominguez A, Sabria M, Ruiz L, Torner N, Cayla J, Barrabeig I, Sala MR, Godoy P, Camps N, Minguell S. Impact of the Legionella urinary antigen test on epidemiological trends in community outbreaks of legionellosis in Catalonia, Spain, 1990-2004. Int J Infect Dis 2009, 13:e365-e370. 10.1016/j.ijid.2009.01.004, 19356959.
36. Eliakim-Raz N, Robenshtok E, Shefet D, Gafter-Gvili A, Vidal L, Paul M, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2012, 9. CD004418.
37. Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 2007, 51:3977-3982. 10.1128/AAC.00006-07, 2151470, 17709460.
38. Bliziotis IA, Michalopoulos A, Kasiakou SK, Samonis G, Christodoulou C, Chrysanthopoulou S, Falagas ME. Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2005, 80:1146-1156. 10.4065/80.9.1146, 16178494.
39. MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005, 41:435-440. 10.1086/432056, 16028149.
40. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 2012, 25:450-470. 10.1128/CMR.05041-11, 3416487, 22763634.
41. Zambon A, Polo Friz H, Contiero P, Corrao G. Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case-control, case-crossover and case-time-control designs. Drug Saf 2009, 32:159-167. 10.2165/00002018-200932020-00008, 19236122.